Kornimate/medical-research-clean huggingface dataset:
communication in icu during covid-19

Conditions: COVID-19; Severe Acute Respiratory Syndrome Coronavirus 2; Severe Acute Respiratory Syndrome

Summary: this study explores the actual situation of communication during the coronavirus disease 2019 (covid-19) pandemic in the south asia and middle east region. the purpose is to assess the effect of the limited visitor policy during the covid-19 pandemic, on the pattern of interaction of critically ill patients to their kin/ guardian and doctor-family members communication. primary objective of this study are as follows: 1. explore the changes in communication pattern with limited contact during the covid-19 pandemic. 2. assess the methods of informed consent in intensive care units (icus) during the same period

an observational, cross-sectional, web-based questionnaire survey, with multi-centre involvement across hospitals in the south asia and middle-east region. the questionnaire consists of two sections. section one obtains information from participants regarding communication and visiting practices in icu during pre-covid-19 era, and the section two obtains information regarding the policy changes if any during the covid-19 pandemic in regards to safety of healthcare workers (hcws) and public. in order to obtain the largest representation of south asia and middle east icus, a network of research doctors as facilitators from each country is created. the role of the facilitators is to contact and recruit adult icus within their country. each facilitator contacts the hospitals (public and private), creating a network of collaborating doctors/nurses (participants) from those hospitals who expressed their willingness to participate. data collection: a web based google forms with online access will be used only one entry per icu will be collected during the study. statistic analysis: a descriptive analysis is planned for the general characteristics of the participating units and the study population.

Eligibility criteria:
inclusion criteria: 1. adult icus, 2. new created covid-19 icus during the pandemic exclusion criteria: 1. paediatric icu 2. neonatal icu

Keywords: communication in icu doctor-family members communication informed consent
clinical and radiographic evaluation of zinc oxide-propolis mixture versus modified triple antibiotic paste in lstr

Conditions: Pain, Postoperative; Periapical; Infection

Summary: the aim of this study is to evaluate and compare the clinical effectiveness of zinc oxide-propolis mixture with triple antibiotic paste in lstr as root canal filling material in necrotic primary molars.

the promising results of propolis as a natural antibiotic in previous in- vivo studies made it interesting to combine propolis to the golden standard zinc oxide eugenol as an intracanal medication in pulp affected primary molars and use this mix as a natural substitute to the modified triple antibiotic paste (m-tap) and therefore overcoming the antibiotic bacterial resistance, allergy and developmental anomalies that might arise in permanent successor teeth from m-tap usage.

Eligibility criteria:
inclusion criteria: * children: 1. cooperative children aged 4 -7 years old. 2. systemically healthy. * teeth: clinical criteria: 1. necrotic primary mandibular second molar teeth. 2. spontaneous pain or tenderness to percussion 3. deep carious lesion with pulp exposure. 4. presence of chronic apical abscess or sinus tract tooth should be restorable. (thakur et al., 2021) radiographic criteria: 1. coronal-radiographic evidence of a deep carious lesions or lesion approximating pulp 2. radicular discontinuity of lamina dura, furcation involvement less than or equal to half of shortest root in vertical dimension. (thakur et al., 2021) exclusion criteria: * children: 1. with physical or emotional alteration. 2. children with systemic disease. 3. previous history of allergy to antibiotics used in the study. 4. children that will not attend follow up. • teeth: 1. non restorable carious primary molars. 2. grade iii mobility

Keywords: propolis modified triple antibiotic paste lesion sterilization and tissue repair
using hypnotherapy for dementia & alzheimer's

Conditions: Alzheimer Disease

Summary: from the past research that has been done the investigators have learned that brain cells die \& leave a deposit in the brain known as beta-amyloid. since alzheimer's is a slow acting disease the natural immune system does not respond to this illness so this builds up in the brain. as it builds up it gets into the neurotransmitters in the brain causing more brain cells to die. as these buildups occur dementia sets in due to more of the brain dying \& effects normal activity. study was cancelled hypnotherapy will be used to do the following things: * increase the immune system * the immune system will begin to clean up the beta-amyloid buildup * that removes damage cells of the brain * increase more blood flow to the brain * allows the active brain cells to be trained to carry out daily activities study was cancelled

hypnotherapy has been used for many things through the years. today many doctors use it for their patients for operations when blood supply is low to control bleeding, pain for difficult dental work, mental issues \& many other things. back in the 1950's a doctor wilhelm reich was able to increase the immune system \& tested it by blood samples. the immune system isn't sending enough white blood cells into the brain to clean up beta-amyloids. using hypnotherapy could increase the white blood cells to the brain to clean up the damage. in theory the primitive part of the brain ( 1%)job is to protect the body from harm. it does this by giving out a fight or flight response to the subconscious mind which is (88%) of our brain. then the conscious mind controls the body to either fight or flight. since alzheimer's is such a slow moving disease the primitive part of the brain does not react because of the slow action. so the subconscious never gets the message that there's a disease in the brain so the body could fight it off. as the immune system cleans up the beta-amyloid buildup the healthy neurotransmitters are able to function. healthy brain cells can be retrained so the quality of life can be more normal. example: \* if you imagine driving down the same path across a field day after day. before to long the grass dies \& ruts start to form. next thing you know your auto is hitting high center. so you have to move over to keep from getting stuck in the ruts. the brain works in the same way. the person do things without thinking because that is how the brain has been trained. but the brain can be retrained to do the functions as it did before the illness. hypnotherapy session will be: * one hour long * one session per month for 9 months * 3 months free of any sessions to measure the effect study was cancelled

Eligibility criteria:
inclusion criteria: * diagnosed having alzheimer * under doctor's care exclusion criteria: * must be able to follow instructions

Keywords: alzheimer dementia
working toward the advancement of recovery using modulated therapeutic hyperthermia (warmth) in sepsis - pilot

Conditions: Sepsis

Summary: the purpose of this pilot study is to demonstrate the ability to warm critically ill patients with sepsis to a target temperature of 39°c

participants with sepsis and without fever will be warmed with surface (forced air and conductive wraps) and core (esophageal) warming, and will have the warming devices placed in the icu. the warming devices will remain in place until the study is completed (36 hours). the heat exchangers will be set to attain a patient target temperature of 39°c as rapidly as possible, after which the forced-air (non-servo) system will be removed, and the conductive system heat exchanger (powering the water blankets and esophageal device, both of which are servo-controlled) will be set to maintain patient temperature at 39°c for the duration of the study period. once goal temperature has been achieved for 2 consecutive hours, the forced air warming device will be discontinued. patients will be randomized at this point to group 1, in which esophageal warming will be discontinued first or to group 2, in which external conductive warming will be discontinued first. all patients will have usual standard of care labs, vital signs, and imaging for patients undergoing mechanical ventilation in the icu. for the duration of the 36-hour intervention, patient vital signs, including blood pressure, heart rate, respiratory rate, and vasopressor requirements will be monitored and recorded every 6 hours. core temperature will be measured and recorded hourly. patient's clinical status and outcome will be reviewed in the medical chart 7 days after study completion.

Eligibility criteria:
inclusion criteria: * patients above the age of 18 years old. * patients with sepsis diagnosed within 48 hours of enrollment. for the purpose of this protocol, sepsis onset is defined as administration of intravenous antibiotics in a patient that the treating critical care physician feels is ill from sepsis. * all qualifying patients must have a sequential organ failure assessment (sofa) score of 2 or greater at the time of enrollment. * patients requiring mechanical ventilation with an expected duration of mechanical ventilation of \>= 2 days. * patient maximum baseline documented temperature (within previous 24 hours) \< 38.3°c. exclusion criteria: * patients without legally authorized representative able to provide informed consent. * patients with contraindication to core warming using an esophageal core warming device, surface warming using conductive heat transfer, and forced air warmer. * patients known to be pregnant. * patients with \<40 kg of body mass. * patients with comfort care only status. * patients with contraindications to hyperthermia treatment (acute stroke, acute traumatic brain injury, acute spinal cord injury, post-cardiac arrest, multiple sclerosis, or sickle cell disease). * expected continuous dialysis within 48 hours after enrollment.

Keywords: hyperthermia fever sepsis
mechanism and effects of manipulating chloride homeostasis in acute heart failure

Conditions: Heart Failure

Summary: the purpose of this study is to understand the effects of chloride supplementation on volume-overloaded acute heart failure patients concomitantly treated with iv diuretics.

the overarching goal of this proposal is to develop a comprehensive understanding of the biology and therapeutic potential of sodium-free chloride supplementation. while sodium homeostasis has been the focus of substantial investigation, very little research has been devoted to understanding chloride homeostasis. thus, this proposal is designed to obtain the full spectrum of information pertaining to chloride, such as novel areas with great interest by the scientific community (i.e. modulation of the wnk-kinase system and the use of exosomes), to more practical/basic questions (i.e. what happens to sodium chloride balance when a patient is challenged with chloride). the proposed outpatient study has been designed to serve as a real world efficacy study. with extensive biobanking and analysis of samples in the proposed setting, there is the potential to be able to deliver a great wealth of information on the biology and therapeutic potential of manipulating chloride homeostasis in heart failure. research confirms that many heart failure therapies demonstrate measurable benefit in highly controlled environments, but lack effectiveness when studied in decompensated patients receiving standard decongestive therapies. as such, this study seeks to understand the effects of chloride supplementation on volume-overloaded patients concomitantly treated with iv diuretics.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of decompensated heart failure with at least one objective sign of volume overload (rales, edema, elevated jugular venous pressure (jvp), or weight gain of at least 5 pounds) * a projected need by the treating clinician for continued treatment with iv diuretics * chronic loop diuretic use exclusion criteria: * inability to commit to or comply with serial visits for treatment in the yale transitional care center (ytcc) * history of severe metabolic or respiratory acidosis within 30 days of enrollment * use of metformin, acetazolamide, or any other agent that could predispose to acidosis. patients who are on metformin may be enrolled if their metformin can be discontinued safely for the duration of the study. any participants who have consistently elevated blood glucose readings \> 200 mg/dl while inpatient will not be enrolled. * serum bicarbonate level \<20mmol/l * estimated glomerular filtration rate \<20 ml/min or renal replacement therapy * appears unlikely, or unable to participate in the required study procedures, as assessed by the study pi or research registered nurse (rn) (ex: clinically-significant psychiatric, addictive, or neurological disease) * inability to give written informed consent or follow study protocol

Keywords: sodium homeostasis
immediate effects of manual therapy versus tens in patients with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: patients with knee osteoarthritis have high prevalence of pain , requiring ever more precise interventions in their management. this study aims to investigate the immediate effects of manual therapy and tens on pain in patients with knee osteoarthritis. knowledge of best interventions favors reducing spending on health and safety for the patient.

this study aims to compare the efficacy of manual therapy and tens for immediate control of pain in patients with knee osteoarthritis. they will be included 62 patients with clinical and radiological diagnosis of knee osteoarthritis, presenting pain of at least 3 in vas, which are recruited from rheumatology and geriatrics clinics in fortaleza / ce through a prior screening. will be three assessments, prior to the intervention, immediately after it and after 72 hours. the data collected shall appear in individual printed records. participants will be divided into two therapy groups, of which one will be applied manual therapy and other tens. there will be randomisation allocation of individuals in the groups and because of the nature of the interventions only the evaluator may be blind. in manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee. in tens group will be applied to continuous current mode, frequency 100hz and pulse width of 50μs for 40 minutes in a single application. the intensity will be defined by the patient, should the stimulus be considered intense, but pleasant to it. the kolmogorov - smirnov test is used to verify the data distribution normality. the characterization of the participants is performed by means of descriptive statistical analysis. parametric or non-parametric tests will be used according to the data distribution normality for comparison between groups at baseline. the evaluator blinding will be tested using the chi -square test by comparing the randomization code with the evaluator opinion. the difference between the groups and their respective confidence intervals will be calculated by linear mixed models using interaction term of "time versus group."

Eligibility criteria:
inclusion criteria: * knee osteoarthritis diagnosed by clinical criteria established by the american college of rheumatology and radiological criteria of kelgren-lawrence * age over 50 years * pain intensity above 2 on the vas exclusion criteria: * other systemic inflammatory disease * changes in sensitivity * use of anti-inflammatory steroids, tranquillizers and/or antidepressants in the last month * analgesic in last 24 hours * use of cardiac pacemaker
refractory chronic cough improvement via nal er (river)

Conditions: Refractory Chronic Cough

Summary: the main purpose of this study is to evaluate the effect of nal er on 24-hour cough frequency and to assess safety and tolerability of nal-er for treatment of refractory chronic cough.


Eligibility criteria:
key inclusion criteria: * diagnosis of refractory chronic cough (rcc) for at least one year * chest radiograph or ct of thorax within 24 months or during screening not demonstrating any significant abnormalities contributing to rcc exclusion criteria: * diagnosis of sleep apnea * respiratory tract infection within 6 weeks of baseline * history of bronchiectasis, copd, or ipf * history of uncontrolled asthma * current smokers/vapers, quit smoking with \ =20 pack years * history of major psychiatric disorder * history of substance abuse * pregnant or lactating females * known intolerance to opioids * abnormal kidney or liver functions based on screening lab results. * known hypersensitivity to nalbuphine or to nal er excipients * previous participation in a nalbuphine er clinical study * use of opiates, benzodiazepines, or maois within 14 days of baseline * use of pregabalin, gabapentin, thalidomide for treatment of cough within 14 days of baseline * use of ace inhibitors within 12 weeks of baseline * use of a medication having a "known risk" of torsade de pointes (categorized as "kr" on the credible meds® website.) 4 weeks prior to baseline * use of unstable doses of medications associated with a potential risk of qt prolongation but not clearly associated with torsade de pointes within 4 weeks of screening. * use of unstable doses of cough suppressants within 14 days of baseline * use of unstable doses of medications that affect serotonergic neurotransmission that may cause serotonin syndrome with opioids within14 days of baseline * use of unstable doses of p450 isozyme inhibitors/inducers within 14 days of baseline other protocol defined inclusion/exclusion criteria may apply.

Keywords: rcc cough nalbuphine
lot consistency study of dtap-ipv-hb-prp~t vaccine administered at 2-4-6 months of age in healthy infants

Conditions: Diphtheria; Tetanus; Pertussis; Hepatitis B; Poliomyelitis

Summary: the purpose of this trial is to clinically confirm that the manufacturing process of the final bulk products of the investigational dtap-ipv-hb-prp\~t vaccine is consistent. the primary objective is to demonstrate the equivalence of three batches of dtap-ipv-hb-prp\~t vaccine, in terms of seroprotection and seroconversion rates for the vaccine antigens after the three-dose primary series. the secondary objectives are: * to describe in each group, the immunogenicity parameters for all antigens one month after the third dose of the primary series * to assess the overall safety in each group one month after the third dose of the primary series.


Eligibility criteria:
inclusion criteria : * two months old infants on the day of inclusion * born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg * informed consent form signed by one or both parents or by the guardian and two independent witnesses * able to attend all scheduled visits and to comply with all trial procedures * received bacillus calmette guerin (bcg) vaccine between birth and one month of life in agreement with the national immunization calendar. exclusion criteria : * participation in another clinical trial in the four weeks preceding the (first) trial vaccination * planned participation in another clinical trial during the present trial period * congenital or acquired immunodeficiency * systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances * chronic illness at a stage that could interfere with trial conduct or completion * blood or blood-derived products received since birth * any vaccination in the four weeks preceding the first trial visit * any planned vaccination (except bcg, rotavirus, and pneumococcal conjugated vaccines) during the study * documented history of pertussis, tetanus, diphtheria, poliomyelitis, haemophilus influenzae type b or hepatitis b infection(s) (confirmed either clinically, serologically or microbiologically) * previous vaccination against hepatitis b, pertussis, tetanus, diphtheria, poliovirus, or haemophilus influenzae type b infection(s) * known personal or maternal history of hiv, hepatitis b (hbsag) or hepatitis c seropositivity * thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination * history of seizures * febrile (rectal equivalent temperature ≥ 38.0°c) or acute illness on the day of inclusion.

Keywords: diphtheria tetanus pertussis hepatitis b poliomyelitis invasive haemophilus influenzae type b.
a mobile phone game to prevent hiv among young africans

Conditions: HIV/AIDS

Summary: this project will test the feasibility of an electronic game to prevent hiv among african preadolescents, delivered via inexpensive android smart phones. in order to collect feasibility data for a future randomized controlled trial, this study involves the pilot-testing of the intervention with a sample of young people in nyanza region, kenya, where 11.4% of young women ages 15-24 are hiv-infected. this feasibility study will be carried out with the kenya medical research institute (kemri).

this project will test the feasibility of an electronic game for preadolescents, delivered via inexpensive android smart phones. the game is informed by socio-behavioral and pedagogical theories, evidence-based practice, and formative research on youth sexual culture in sub-saharan africa. it is designed to: educate young players, ages 11-14, about sexual health and hiv/aids; build risk-reduction skills and related self-efficacy for prevention of hiv, sexually transmitted infections (stis), and unintended pregnancy; challenge harmful gender norms and hiv stigma; and foster dialogue with parents and caregivers. the proposed feasibility test will be conducted in western kenya. sixty preadolescents will be enrolled in the trial, 30 in the study arm and 30 in the control arm. the kenya medical research institute (kemri) has established community advisory boards (cabs) in kisumu, which will be available to the proposed study. data collection will take place at kemri offices, health clinics, or in the meeting room of a local community-based organization (cbo). in addition, data on game-play will be automatically collected on mobile phones given to preadolescent study participants.

Eligibility criteria:
inclusion criteria: * aged 11-14 at time of recruitment * resident in nyanza region, kenya * having basic literacy in english * only one child enrolled per family exclusion criteria: * aged \ 14 at time of recruitment * not resident in nyanza region, kenya * without basic literacy in english * sibling to a child already enrolled in the study * participant in formative research to inform the study

Keywords: hiv prevention preadolescence mobile phone game feasibility
breestim for motor recovery in chronic stroke with moderate impairment (pilot).

Conditions: Motor Recovery

Summary: the overall goal is to investigate the effectiveness of a novel intervention - breathing-controlled electrical stimulation (breestim) on finger flexor spasticity reduction and hand function improvement in chronic stroke with moderate impairment.


Eligibility criteria:
inclusion criteria: * has post stroke ≥ 6 months , medically stable; * unilateral, single stroke (no restriction on type (ischemic or hemorrhagic) or volume (large or small) of stroke); * mas score ≥ 1, i.e., detectable finger flexor hypertonia; exclusion criteria include: * patients with visual deficit/neglect; hearing or cognitive impairment; * patients with history of pulmonary disease (asthma, chronic obstruction pulmonary disease, copd); * patients that are currently adjusting tone alternating medications (e.g., baclofen), or * patients received botulinum toxin injection to the arm/fingers \<4 months, or phenol injections \< 2 years; * patients with a pacemaker; * women who are pregnant.

Keywords: finger flexor spasticity motor recovery breestim